CVS Health Corp. Stock
CVS Health Corp. Stock
CVS Health (symbol CVS) is a health care company that operates a retail pharmacy chain and offers health care services. The company is headquartered in Rhode Island, USA and has more than 9,900 locations. CVS Health operates three business segments: Pharmacy Services, Retail/LTC and Health Care Benefits. The Pharmacy Services segment offers pharmacy benefit management solutions and includes CVS Caremark, which serves more than 94 million plan members. The Retail/LTC segment operates CVS Pharmacy, the largest pharmacy chain in the United States, and provides long-term care pharmacy services through Omnicare. The Health Care Benefits segment offers a range of health insurance products and services through Aetna, which was acquired by CVS Health in 2018.
Pros and Cons of CVS Health Corp. in the next few years
Pros
Cons
Performance of CVS Health Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CVS Health Corp. | 0.310% | -2.916% | 0.751% | 67.192% | 33.871% | 34.582% | 31.403% |
| McKesson Corp. | -0.530% | 3.587% | 13.551% | 20.013% | 6.406% | 102.919% | 334.868% |
| Cardinal Health Inc. | -0.550% | -0.806% | -5.243% | 42.495% | 11.805% | 136.836% | 293.528% |
| AmerisourceBergen Corp. | 1.140% | 1.007% | 9.326% | 6.030% | -6.103% | 59.991% | 160.385% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.CVS Health’s FY2025 results present a striking contrast between robust top-line expansion and severely compressed profitability. Revenue crossed the $402 billion mark, yet net income attributable to shareholders shrank to roughly $1.77 billion from $4.61 billion the prior year—a decline of more than 60%. The reported net margin of just 0.44% and an operating margin of 1.16% highlight a year in which substantial one-time charges overshadowed the underlying business dynamics. Despite this, the share price rebounded from $44.25 at end-2024 to $80 by December 2025, which could suggest that investors looked through the non-cash impairment to focus on cash generation and the potential for earnings recovery.
Revenue growth of nearly 8% appears to have been driven primarily by higher premiums and product sales, while gross margin held fairly steady around 45%—a modest improvement over FY2024. The critical drag on operating profit was a $5.7 billion goodwill impairment in the Health Services segment, which single-handedly pushed reported operating income down to $4.66 billion. Absent that charge, operating earnings could have been roughly in line with or above the prior year’s $8.5 billion, though the trend of declining operating margins in earlier years—from 3.84% in FY2023 to 2.28% in FY2024—suggests that margin pressure was already present. The net impact is a business where top-line growth is being absorbed by rising costs or structural headwinds, with the impairment acting as a forceful acknowledgment of lower expectations for that segment.
From a balance-sheet standpoint, CVS Health appears conservatively capitalized. Total debt is offset by a healthy cash and short-term investment position, resulting in negative net debt and a debt-to-equity ratio of essentially zero. This net cash position provides a considerable buffer. However, working capital management paints a different picture: the current ratio of 0.84 and quick ratio of 0.63 are relatively low for a healthcare enterprise, potentially reflecting the significant insurance payables and pharmacy claims processing flows that tie up liquidity. The goodwill balance itself fell from $91.3 billion to $85.5 billion, primarily due to the Health Services writedown, but intangible-heavy assets still dominate the balance sheet.
Comments